Type III SS again [🇷 for BE/BA]

posted by yjlee168 Homepage – Kaohsiung, Taiwan, 2009-09-07 20:08 (6119 d 07:11 ago) – Posting: # 4159
Views: 15,547

Dear Elmaestro,

❝ [...] It always will be when the single-term-deletion strategy is followed. This is because the model without Sequence as a factor includes Subjects. The subjects are "nested in sequence" (no pun intended!), so your sequence effect becomes effectively zero* (or to say it differently: you cannot [...]



Because each subject just has one and the only one seq in a crossover study, so subj:seq is just the same as subj. However, it is interesting to find out that R treats the model of (lnAUC ~ seq + prd + trt + subj) and the other model of (lnAUC ~ seq + prd + trt + subj:seq) sightly differently through drop1() function to calculate type III SS that we've already had many discussion when we announce bear at this Forum.

❝ [...] odd stuff for nested data. R does it un critically, SAS does some clever work for you, and therefore the SAS type III output differs from R's drop1 output.


As far as I know, for a balanced 2x2x2 crossover study, the SAS-calculated type III SS should be the same as the type I SS. Both should be the same as those calculated by R's drop1(). You said they're different. Could you explain more? Thanks.

❝ [...] the actual Sequence effect. Although I am not a fan of SAS, I totally agree on this specific issue.


Indeed.

All the best,
-- Yung-jin Lee
bear v2.9.6:- created by Hsin-ya Lee & Yung-jin Lee
Kaohsiung, Taiwan https://www.pkpd168.com/bear
Download link (updated) -> here

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
108 visitors (0 registered, 108 guests [including 18 identified bots]).
Forum time: 03:20 CEST (Europe/Vienna)

In theory, there is no difference between theory and practice.
But, in practice, there is.    Jan L.A. van de Snepscheut

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5